Switzerland Allows Use Of US-Origin Products For Comparability With Biosimilars
Executive Summary
The Swiss therapeutics products regulator has revised its policy on the authorization of biosimilars, and is now accepting reference products originating from the US for demonstrating the comprehensive comparability of biosimilars. It has also updated its guideline to explain bridging requirements as per the revised policy.